(St. Paul, MN) Australia-based Cynata Therapeutics signed an agreement with Wuxi AppTech to conduct pre-clinical safety studies with a new stem cell technology.
Cynata Therapeutics Inks Contract for Stem Cell Studies with WuXi AppTec (Proactive Investors)
